I just started investing in this company recently. I don't know the management well yet, but I love their science programs. They are using heterobifunctional degraders like with $ARVN.
1/ Their first indication is IRAK4 in inflammation. This is known to play a big role in inflammation and oncology. They are targeting multiple indications for inflammation.
2/ So far there is only biomarker data, but that is encouraging. The potential of IRAK4 in inflammation could be worth a billion per indication. I think $3 to $5 billion is not unrealistic should it work out as well as hoped.
3/ They are also developing IRAK4+IMID for MYD88 driven cancers. Their lead indication is DLBCL. This is the largest of lymphoma indications. This could be worth up to $750 million sales potential.
4/ Their next set of programs are around STAT3. I have seen a lot of drugs come and go for the JAK/STAT pathway. There are 4 variants of JAK and 6 or 7 with STAT.
5/ They are targeting STAT3 in liquid tumor and fibrotic disorders. There isn't enough information about this program or the patient populations to make any guess about the potential. I do know it could do well over $1 billion if it does well.
6/ Their $3 billion market cap seems extremely expensive for a phase 1 company with just a handful of biomarker data. The expectations are very high with this name. I get the love as I find it the most exciting of the protein degrader companies.
7/ I think valuation should be closer to $2 billion or $40 per share. They need a lot more data on efficacy to show this will be as awesome as we all hope it will be.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
I am still into the buy the dips and sell every rip. I think the collapse in the bubbles in the biotech space are just getting started.
Pathways:
$BPMC 3.36% core position
$TPTX 3.36% core position
$RVMD 2.02% expendable into any big rally
$ERAS 1.34% expendable into any big rally
$RLAY 2.02% expendable into any big rally
Synthetic Lethality:
$MRTX 3.36% core position
$SDGR 2.02% working to pay off core position
$RPTX 2.69% working to pay off core position
I have been in this company for about 8 months now. I think the management is good, but way too early to tell. They are my small cap high risk play.
1/ They are using CAAR-T to target autoimmune disorders. They use a CAAR receptor that encodes a self antigen that drives auto immune disease. The concept is the self reactive B cells should target binding to the CAAR receptor and the T cell would kill them.
2/ Based on the really low level of memory B cells in the body, it could be very difficult to clear them out. Its a high risk play, but if it works, it could be a huge opportunity.
This is a newer company that just went off its lock up period. I don't know the management that well, but it can't be any worse than the disastrous $IOVA. That company is completely broken.
1/ They are working on Tumor Infiltrating Lymphocytes (TIL). This is the most successful use of TCR therapies in solid tumors. This starts with removing a met or doing a biopsy of the tumor. It takes that tumor and breaks it down to get all the antigens for that specific patient.
2/ Those tumor antigens are introduced to the patient's own T cells in the lab to activate them toward those antigens. Those T cells are then put back into the patient with PD1 to target and kill all tumor cells and mets.
This is a new IPO and they are still within the lock up period until late January. I have followed them as a private company at the ARM conferences as part of my overall CRISPR research for years.
1/ I can safely say I feel this is a good management team at this early stage of the game. They are the original CRISPR company holding all the original patents. They also pioneered new technology with chRDNA.
2/ I classify them as cell therapies because that is where their focus is. They have 3 allogeneic CAR-T programs in development while building an iPSC manufacturing for iNK and iT cells.
This is a newer company that recently IPO'd. They are still in the lock up period until mid December. I don't know anything about their management yet. They are working on iPSC cell manufacturing using CRISPR MAD7 editing.
1/ The MAD7 resembles the Cfp1 CAS enzyme. They are focused on developing 2 NK cell programs as their lead programs. They have CNTY-101 which is a standard CD19 and they have CNTY-103 which has CD133.
2/ They are targeting GBM with CNTY-103 which makes this a completely unique program compared to what some other companies are doing. They have some other early CAR-NK and CAR-T programs in development using iPSC.
I have only been in $SANA for about 6 months, but I really like their 2 franchises. I also like their management team, although, I don't know them that well.
1/ Their first franchise is the Fusogen programs. This is all about delivering any genetic payload to cells. Their fusogen platform uses virus like particles. If we treated this as a stand alone biotech, I would value it around $1 billion to $1.5 billion.
2/ Their second platform is working to build iPSC manufacturing around hypoimmune cells. This will be right along the lines of what $FATE has built. I would also value this platform around $1 billion to $1.5 billion.